Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07406243 · ClinicalTrials.gov registry record · NA
Oral Antioxidant Therapy Targeted to the Mitochondria for Improving Brain Artery Health in Postmenopausal Women
A NA study, sponsored by Colorado State University.
- Not yet
- Registry status
- NA
- Development phase
- 86
- Enrollment target
NCT07406243 is a NA study that has not yet begun recruiting, run by Colorado State University. The registered enrollment target is 86 participants.
The verdict
NCT07406243, a NA study, has not yet begun recruiting, sponsored by Colorado State University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 86 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if 3 months of taking the dietary supplement MitoQ \[a mitochondria-targeted antioxidant that targets to reduce mitochondrial reactive oxygen species (mitoROS)\] works to treat age- and menopause-related reductions in brain artery (cerebrovascular) function in postmenopausal women 60 years of age or older free of clinical disease. The main questions it aims to answer are: Does MitoQ improve cerebrovascular function in postmenopausal women? If so, does MitoQ improve cerebrovascular function by lowering mitoROS in these arteries? Researchers will compare MitoQ to a placebo (a look-alike substance that contains no drug) to see if MitoQ can improve cerebrovascular function by lowering mitoROS in arteries involved in brain health and function. Participants will: Take MitoQ (20 mg/day) or a placebo every day for 3 months Visit the research laboratory at baseline and then after 3 months for cerebrovascular testing; there is also a check-in visit at 6 weeks, which is the halfway point Keep track of symptoms and events during their treatment period to report to the study team
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Mitoquinone (MitoQ)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2026-04 |
| Est. Completion | 2030-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07406243
The ClinicalTrials.gov registry entry for NCT07406243 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Colorado State University, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07406243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07406243 about?
NCT07406243 is a clinical study titled "Oral Antioxidant Therapy Targeted to the Mitochondria for Improving Brain Artery Health in Postmenopausal Women". The goal of this clinical trial is to learn if 3 months of taking the dietary supplement MitoQ \[a mitochondria-targeted antioxidant that targets to reduce mitochondrial reactive oxygen species (mitoROS)\] works to treat age- and menopause-related reductions in brain artery (cerebrovascular) functio...
What is the current status of trial NCT07406243?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 86 participants. The study started on 2026-04. Estimated completion is 2030-07.
What interventions are being tested in trial NCT07406243?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Mitoquinone (MitoQ) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07406243?
This trial is sponsored by Colorado State University, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.